Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020-2022)

Basit Öğe Kaydı
dc.authoridSimsek, Melih/0000-0003-0633-8558|alan, ozkan/0000-0002-6635-2012|Özönder Ünal, Ipek/0000-0003-3509-0061|Ünal, Çağlar/0000-0003-3245-1570|Tuncer, Gulsah/0000-0002-9841-9146|Okutur, Kerem/0000-0002-8079-7739|SAKIN, Abdullah/0000-0003-2538-8569
dc.authorwosidSimsek, Melih/AFM-5523-2022
dc.authorwosidalan, ozkan/AAV-5044-2020
dc.authorwosidÖzönder Ünal, Ipek/JHU-3176-2023
dc.authorwosidÜnal, Çağlar/ITT-4695-2023
dc.contributor.authorUnal, Caglar
dc.contributor.authorTuncer, Gulsah
dc.contributor.authorCopur, Betul
dc.contributor.authorPilanci, Kezban Nur
dc.contributor.authorOkutur, Kerem Sadi
dc.contributor.authorYararbas, Kanay
dc.contributor.authorAlan, Ozkan
dc.date.accessioned2024-07-18T20:55:11Z
dc.date.available2024-07-18T20:55:11Z
dc.date.issued2023
dc.departmentİstanbul Bilgi Üniversitesien_US
dc.description.abstractObjectiveWe aimed to identify a rapid, accurate, and accessible biomarker in the early stages of COVID-19 that can determine the prognosis of the disease in cancer patients.MethodsA total number of 241 patients with solid cancers who had a COVID-19 diagnosis between March 2020 and February 2022 were included in the study. Factors and ten different markers of inflammation were analyzed by year of diagnosis of COVID-19 and grouped by severity of infection.ResultsHospitalization, referral to the intensive care unit (ICU), mechanical ventilation, and death were more frequent in 2020 than in 2021 and 2022 (mortality rates, respectively, were 18.8%, 3.8%, and 2.5%). Bilateral lung involvement and chronic lung disease were independent risk factors for severe disease in 2020. In 2021-2022, only bilateral lung involvement was found as an independent risk factor for severe disease. The neutrophil-to-lymphocyte platelet ratio (NLPR) with the highest area under the curve (AUC) value in 2020 had a sensitivity of 71.4% and specificity of 73.3% in detecting severe disease (cut-off > 0.0241, Area Under the Curve (AUC) = 0.842, p <.001). In 2021-2022, the sensitivity of the C-reactive protein-to-lymphocyte ratio (CRP/L) with the highest AUC value was 70.0%, and the specificity was 73.3% (cut-off > 36.7, AUC = 0.829, p = .001).ConclusionsThis is the first study to investigate the distribution and characteristics of cancer patients, with a focus on the years of their COVID-19 diagnosis. Based on the data from our study, bilateral lung involvement is an independent factor for severe disease, and the CRP/L inflammation index appears to be the most reliable prognostic marker.en_US
dc.identifier.doi10.1080/03007995.2023.2223917
dc.identifier.endpage996en_US
dc.identifier.issn0300-7995
dc.identifier.issn1473-4877
dc.identifier.issue7en_US
dc.identifier.pmid37300513en_US
dc.identifier.scopus2-s2.0-85163218672en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage987en_US
dc.identifier.urihttps://doi.org/10.1080/03007995.2023.2223917
dc.identifier.urihttps://hdl.handle.net/11411/8765
dc.identifier.volume39en_US
dc.identifier.wosWOS:001012017900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofCurrent Medical Research and Opinionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCanceren_US
dc.subjectCovıd-19en_US
dc.subjectİnflammation İndexesen_US
dc.subjectCrpen_US
dc.subjectLen_US
dc.subjectNlpren_US
dc.subjectSars-Cov-2en_US
dc.subjectResponse Indexen_US
dc.subjectPneumoniaen_US
dc.titleClinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020-2022)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Web of Science Indexed Publications
PubMed Indexed Publications
Scopus Indexed Publications